Study of effectiveness and safety of rosuvastatin, aspirin and clopidogrel in patients with acute coronary syndrome
Not Applicable
- Conditions
- Health Condition 1: I20-I25- Ischemic heart diseases
- Registration Number
- CTRI/2019/01/017221
- Lead Sponsor
- Aprica Healthcare Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Adult patients of either sex of 30 to 85 years of age (inclusive both) with evidence of coronary artery disease and/or Post PCI, or having risk of coronary artery disease as determined by clinical judgment of clinician
2.Patients receiving treatment of fixed dose combination of Rosuvastatin, Aspirin and clopidogrel
3.Patient willing to provide written informed consent document
Exclusion Criteria
1.Patients receiving any other lipid lowering agent than study drug i.e. rosuvastatin
2.Patients receiving any other antiplatelet agent than aspirin and clopidogrel
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate efficacy of treatment by studying changes in following parameters. <br/ ><br>1. CHA2DS2-VASc Score <br/ ><br>2. Lipid levels <br/ ><br>3. Cardiovascular morbidity and mortalityTimepoint: 4, 12 and 24 weeks
- Secondary Outcome Measures
Name Time Method Secondary outcome meausures will be <br/ ><br>1. Mean changes in Systolic and diastolic blood pressure <br/ ><br>2.Changes in ECG parameters at 4, 12 and 24 weeks <br/ ><br>3.Number of patients achieving target levels of lipid levels <br/ ><br>4.Treatment responders <br/ ><br>5.Incidence and type of any clinical or laboratory adverse experiences. <br/ ><br>6.Socioeconomic classification of patients <br/ ><br>Timepoint: 4, 12 and 24 weeks